- Conditions
- Contraception
- Interventions
- Relugolix Combination Therapy
- Drug
- Lead sponsor
- Sumitomo Pharma Switzerland GmbH
- Industry
- Eligibility
- 18 Years to 50 Years · Female only
- Enrollment
- 1,164 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 109
- States / cities
- Mobile, Alabama • Chandler, Arizona • Mesa, Arizona + 89 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–15
of 15
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Endometriosis Related Pain
- Interventions
- Relugolix, Estradiol/norethindrone acetate, Estradiol/norethindrone acetate placebo, Relugolix placebo
- Drug
- Lead sponsor
- Myovant Sciences GmbH
- Industry
- Eligibility
- 18 Years to 50 Years · Female only
- Enrollment
- 638 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 43
- States / cities
- Dothan, Alabama • Mesa, Arizona • Scottsdale, Arizona + 37 more
- Conditions
- Endometriosis Related Pain
- Interventions
- Relugolix, Estradiol/norethindrone acetate, Estradiol/norethindrone acetate placebo, Relugolix placebo
- Drug
- Lead sponsor
- Myovant Sciences GmbH
- Industry
- Eligibility
- 18 Years to 50 Years · Female only
- Enrollment
- 623 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 41
- States / cities
- Andalusia, Alabama • Washington D.C., District of Columbia • Aventura, Florida + 36 more
- Conditions
- Heavy Menstrual Bleeding, Uterine Fibroid
- Interventions
- Relugolix, Estradiol/norethindrone acetate, Relugolix placebo, Estradiol/norethindrone acetate placebo
- Drug
- Lead sponsor
- Myovant Sciences GmbH
- Industry
- Eligibility
- 18 Years to 50 Years · Female only
- Enrollment
- 382 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 89
- States / cities
- Birmingham, Alabama • Mesa, Arizona • Tucson, Arizona + 78 more
- Conditions
- Pregnancy Related, Pregnancy Complications, Pregnancy, High Risk
- Interventions
- Relugolix + Estradiol + Norethindrone Acetate
- Drug
- Lead sponsor
- Sumitomo Pharma Switzerland GmbH
- Industry
- Eligibility
- 18 Years to 50 Years · Female only
- Enrollment
- 530 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Marlborough, Massachusetts
- Conditions
- Healthy
- Interventions
- Relugolix/E2/NETA FDC, Relugolix, Erythromycin
- Drug
- Lead sponsor
- Myovant Sciences GmbH
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 43 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021
- U.S. locations
- 1
- States / cities
- Hialeah, Florida
- Conditions
- Heavy Menstrual Bleeding, Uterine Fibroid
- Interventions
- Relugolix, Estradiol/norethindrone acetate
- Drug
- Lead sponsor
- Myovant Sciences GmbH
- Industry
- Eligibility
- 18 Years to 50 Years · Female only
- Enrollment
- 477 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 104
- States / cities
- Andalusia, Alabama • Birmingham, Alabama • Mobile, Alabama + 84 more
- Conditions
- Endometriosis
- Interventions
- 40 mg relugolix, 1 mg estradiol, 0.5 mg norethindrone acetate
- Drug
- Lead sponsor
- Main Line Health
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 110 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 1
- States / cities
- Wynnewood, Pennsylvania
- Conditions
- Uterine Fibroids, Endometriosis
- Interventions
- Relugolix Combination Tablet
- Drug
- Lead sponsor
- Sumitomo Pharma Switzerland GmbH
- Industry
- Eligibility
- 18 Years to 50 Years · Female only
- Enrollment
- 1,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2030
- U.S. locations
- 120
- States / cities
- Mobile, Alabama • Chandler, Arizona • Mesa, Arizona + 98 more
- Conditions
- Metrorrhagia, Pelvic Pain, Menorrhagia, Leiomyoma
- Interventions
- Myfembree Oral Product
- Drug
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 18 Years and older · Female only
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2024
- U.S. locations
- 6
- States / cities
- Chicago, Illinois • Flossmoor, Illinois • Orland Park, Illinois + 1 more
- Conditions
- Pelvic Pain
- Interventions
- Relugolix (40 mg) /estradiol (1 mg)/norethisterone acetate (0.5 mg) oral tablet
- Drug
- Lead sponsor
- Endeavor Health
- Other
- Eligibility
- 18 Years to 35 Years · Female only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- Evanston, Illinois
- Conditions
- Uterine Leiomyoma, Uterine Fibroids
- Interventions
- Relugolix, Estradiol/norethindrone acetate, Placebo for relugolix, Placebo for E2/NETA
- Drug
- Lead sponsor
- Myovant Sciences GmbH
- Industry
- Eligibility
- 18 Years to 51 Years · Female only
- Enrollment
- 229 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 72
- States / cities
- Birmingham, Alabama • Mesa, Arizona • Tucson, Arizona + 61 more
- Conditions
- Endometriosis
- Interventions
- Relugolix, Estradiol/norethindrone acetate
- Drug
- Lead sponsor
- Myovant Sciences GmbH
- Industry
- Eligibility
- 18 Years to 51 Years · Female only
- Enrollment
- 802 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 60
- States / cities
- Andalusia, Alabama • Scottsdale, Arizona • Tucson, Arizona + 50 more
- Conditions
- Endometriosis, Pelvic Pain
- Interventions
- Relugolix CT
- Drug
- Lead sponsor
- University of Michigan
- Other
- Eligibility
- 18 Years to 49 Years · Female only
- Enrollment
- 130 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Heavy Menstrual Bleeding, Uterine Fibroid
- Interventions
- Relugolix, Estradiol/norethindrone acetate, Estradiol/norethindrone acetate placebo, Relugolix placebo
- Drug
- Lead sponsor
- Myovant Sciences GmbH
- Industry
- Eligibility
- 18 Years to 50 Years · Female only
- Enrollment
- 388 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 76
- States / cities
- Andalusia, Alabama • Mobile, Alabama • Little Rock, Arkansas + 62 more